Background:  The purpose of PARAGON is to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular (CV) death and HF hospitalizations in patients with HF with preserved EF (HFpEF) Trial Registration No: NCT02625922 (clinicaltrials.gov) Link  Trial Status: Randomized worldwide: 4600, Recruitment stopped Randomized in Basel: 7 Enrolling Centers:  Switzerland Worldwide: Basel, Zürich, Bern, Lausanne,   39 in different countries  Biel, Lugano Core Study Team: 
© Christian Mueller, 2012 - 2018 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: October 2018
Jasmin Martin Brigitte Fitze Rahel Isenrich Home News Team Studies Publications Events Cooperations Contact Max Rieger Kristin Podkowik Bettina Glatz Beate Hartmann Ph.D.